0001121702-20-000081 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2020	Nov. 09, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Entity Registrant Name	YIELD10 BIOSCIENCE, INC.
Entity Central Index Key	0001121702
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,334,048

CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 2,995	$ 5,417
Short-term investments	8,794	5,700
Accounts receivable	148	72
Unbilled receivables	56	20
Prepaid expenses and other current assets	368	475
Total current assets	12,361	11,684
Restricted cash	254	332
Property and equipment, net	935	1,243
Right-of-use assets	2,796	3,141
Other assets	300	318
Total assets	16,646	16,718
Current Liabilities:
Accounts payable	103	279
Accrued expenses	930	1,326
Lease liabilities	443	602
Total current liabilities	1,476	2,207
Lease liabilities, net of current portion	3,283	3,619
Warrant liability	0	14,977
Other long-term liabilities	15		$ 0
Total liabilities	4,774	20,803
Commitments and contingencies (Note 10)
Series B Convertible Preferred Stock ($0.01 par value per share); 0 and 5,750 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	0	0	0
Stockholders’ Equity (Deficit):
Series A Convertible Preferred Stock ($0.01 par value per share); 0 shares and 796 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at September 30, 2020 and December 31, 2019; 3,330,778 and 933,423 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	33	9
Additional paid-in capital	384,465	360,926
Accumulated other comprehensive loss	(168)	(126)
Accumulated deficit	(372,458)	(364,894)
Total stockholders’ equity (deficit)	11,872	(4,085)	$ 5,698
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 16,646	$ 16,718

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue	$ 204	$ 224	$ 604	$ 666
Expenses:
Research and development	1,300	1,232	3,939	3,646
General and administrative	1,098	990	3,664	3,201
Total expenses	2,398	2,222	7,603	6,847
Loss from operations	(2,194)	(1,998)	(6,999)	(6,181)
Other income (expense):
Change in fair value of warrants	0	0	(957)	0
Loan forgiveness income (Note 9)	0	0	333	0
Other income (expense), net	37	16	85	68
Total other income (expense)	37	16	(539)	68
Net loss before income tax expense	(2,157)	(1,982)	(7,538)	(6,113)
Income tax expense	(11)	0	(26)	0
Net loss	$ (2,168)	$ (1,982)	$ (7,564)	$ (6,113)
Basic and diluted net loss per share (in USD per share)	$ (0.87)	$ (6.33)	$ (3.69)	$ (20.64)
Number of shares used in per share calculations:
Basic and diluted (in shares)	2,492,274	312,952	2,050,726	296,139
Grant
Revenue:
Revenue	$ 204	$ 224	$ 604	$ 666

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Series B Convertible Preferred Stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Series B Convertible Preferred Stock, issued (in shares)	0	5,750
Series B Convertible Preferred Stock, outstanding (in shares)	0	5,750
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, issued (in shares)	0	796
Preferred stock, outstanding (in shares)	0	796
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	60,000,000	60,000,000
Common stock, issued (in shares)	3,330,778	933,423
Common stock, outstanding (in shares)	3,330,778	933,423

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS UNAUDITED - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (2,168)	$ (1,982)	$ (7,564)	$ (6,113)
Other comprehensive loss
Change in unrealized gain (loss) on investments	(6)	0	1	0
Change in foreign currency translation adjustment	5	(6)	(43)	(14)
Total other comprehensive loss	(1)	(6)	(42)	(14)
Comprehensive loss	$ (2,169)	$ (1,988)	$ (7,606)	$ (6,127)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (7,564)	$ (6,113)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	137	150
Change in fair value of warrants	957	0
Loss on disposal of fixed assets	206	0
Charge for 401(k) company common stock match	95	73
Stock-based compensation	506	406
Non-cash lease expense	345	456
Deferred income tax provision	33	0
Changes in operating assets and liabilities:
Accounts receivable	(76)	23
Unbilled receivables	(36)	(17)
Prepaid expenses and other assets	92	217
Accounts payable	(228)	(66)
Accrued expenses	(324)	48
Lease liabilities	(495)	(622)
Other liabilities	15	0
Net cash used for operating activities	(6,337)	(5,445)
Cash flows from investing activities
Purchase of property and equipment	(42)	(12)
Proceeds from sale of property and equipment	10	0
Purchase of short-term investments	(6,290)	(1,000)
Proceeds from the sale and maturity of short-term investments	3,197	3,746
Net cash (used for) provided by investing activities	(3,125)	2,734
Cash flows from financing activities
Proceeds from warrants exercised (Note 12)	1,658	0
Proceeds from public and private offerings, net of issuance costs	5,367	2,583
Taxes paid on employees' behalf related to vesting of stock awards	(17)	(4)
Net cash provided by financing activities	7,008	2,579
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(46)	(14)
Net decrease in cash, cash equivalents and restricted cash	(2,500)	(146)
Cash, cash equivalents and restricted cash at beginning of period	5,749	3,355
Cash, cash equivalents and restricted cash at end of period	3,249	3,209
Supplemental disclosure of non-cash information:
Offering costs remaining in accrued expenses	$ 63	$ 41

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Series A Preferred Stock Series A Convertible Preferred Stock	Series A Preferred Stock Common Stock	Series A Preferred Stock Additional Paid-In Capital	Series B Preferred Stock	Series B Preferred Stock Common Stock	Series B Preferred Stock Additional Paid-In Capital
Balance (in shares) at Dec. 31, 2018		0	250,631
Balance at Dec. 31, 2018	$ 5,698	$ 0	$ 3	$ 357,743	$ (110)	$ (351,938)
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	406			406
Issuance of common stock for 401k match (in shares)			1,671
Issuance of common stock for 401(k) match	64			64
Issuance of stock for restricted stock unit vesting, net of 2,449 shares withheld for employee taxes (in shares)			116
Issuance of stock for restricted stock unit vesting, net of 2,449 shares withheld for employee taxes	(4)			(4)
Issuance of common stock for stock offerings (in shares)			60,541
Issuance of common stock for stock offerings, net of offering costs	2,583			2,583
Effect of foreign currency translation and unrealized loss on investments	(14)				(14)
Net loss	(6,113)					(6,113)
Balance (in shares) at Sep. 30, 2019		0	312,959
Balance at Sep. 30, 2019	$ 2,620	$ 0	$ 3	360,792	(124)	(358,051)
Series B Convertible Preferred Stock, outstanding (in shares) at Dec. 31, 2018	0
Series B Convertible Preferred Stock, outstanding at Dec. 31, 2018	$ 0
Series B Convertible Preferred Stock, outstanding (in shares) at Sep. 30, 2019	0
Series B Convertible Preferred Stock, outstanding at Sep. 30, 2019	$ 0
Balance (in shares) at Jun. 30, 2019		0	312,352
Balance at Jun. 30, 2019	4,454	$ 0	$ 3	360,638	(118)	(356,069)
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	131			131
Issuance of common stock for 401k match (in shares)			607
Issuance of common stock for 401(k) match	23			23
Effect of foreign currency translation and unrealized loss on investments	(6)				(6)
Net loss	(1,982)					(1,982)
Balance (in shares) at Sep. 30, 2019		0	312,959
Balance at Sep. 30, 2019	$ 2,620	$ 0	$ 3	360,792	(124)	(358,051)
Series B Convertible Preferred Stock, outstanding (in shares) at Jun. 30, 2019	0
Series B Convertible Preferred Stock, outstanding at Jun. 30, 2019	$ 0
Series B Convertible Preferred Stock, outstanding (in shares) at Sep. 30, 2019	0
Series B Convertible Preferred Stock, outstanding at Sep. 30, 2019	$ 0
Balance (in shares) at Dec. 31, 2019		796	933,423
Balance at Dec. 31, 2019	(4,085)	$ 0	$ 9	360,926	(126)	(364,894)
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	597			597
Issuance of common stock for 401k match (in shares)			17,518
Issuance of common stock for 401(k) match	86			86
Issuance of common stock for warrant exercise (in shares)			207,296
Issuance of common stock for warrant exercise (Note 12)	1,658		$ 2	1,656
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)							(796)	99,500		(5,750)	718,750
Issuance of common stock upon conversion of Convertible Preferred Stock								$ 2	$ (2)		$ 7	$ (7)
Issuance of common stock upon vesting of restricted stock units (in shares)			6,006
Issuance of common stock upon vesting of restricted stock units	(17)			(17)
Reclassification of warrant liability to equity	15,934			15,934
Issuance of common stock for stock offerings (in shares)			1,348,285
Issuance of common stock for stock offerings, net of offering costs	5,305		$ 13	5,292
Effect of foreign currency translation and unrealized loss on investments	(42)				(42)
Net loss	(7,564)					(7,564)
Balance (in shares) at Sep. 30, 2020		0	3,330,778
Balance at Sep. 30, 2020	$ 11,872	$ 0	$ 33	384,465	(168)	(372,458)
Series B Convertible Preferred Stock, outstanding (in shares) at Dec. 31, 2019	5,750
Series B Convertible Preferred Stock, outstanding at Dec. 31, 2019	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)							(796)	99,500		(5,750)	718,750
Series B Convertible Preferred Stock, outstanding (in shares) at Sep. 30, 2020	0
Series B Convertible Preferred Stock, outstanding at Sep. 30, 2020	$ 0
Balance (in shares) at Jun. 30, 2020		0	1,972,798
Balance at Jun. 30, 2020	8,487	$ 0	$ 20	378,924	(167)	(370,290)
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	243			243
Issuance of common stock for 401k match (in shares)			3,689
Issuance of common stock for 401(k) match	23			23
Issuance of common stock upon vesting of restricted stock units (in shares)			6,006
Issuance of common stock upon vesting of restricted stock units	(17)			(17)
Issuance of common stock for stock offerings (in shares)			1,348,285
Issuance of common stock for stock offerings, net of offering costs	5,305		$ 13	5,292
Effect of foreign currency translation and unrealized loss on investments	(1)				(1)
Net loss	(2,168)					(2,168)
Balance (in shares) at Sep. 30, 2020		0	3,330,778
Balance at Sep. 30, 2020	$ 11,872	$ 0	$ 33	$ 384,465	$ (168)	$ (372,458)
Series B Convertible Preferred Stock, outstanding (in shares) at Jun. 30, 2020	0
Series B Convertible Preferred Stock, outstanding at Jun. 30, 2020	$ 0
Series B Convertible Preferred Stock, outstanding (in shares) at Sep. 30, 2020	0
Series B Convertible Preferred Stock, outstanding at Sep. 30, 2020	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]
Shares withheld for employee taxes (in shares)			2,449
Offering costs	$ 425	$ 425	$ 349

ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

ACCOUNTING POLICIES

Principles of Consolidation

The Company's unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.

Reverse Stock Split

On January 15, 2020, the Company effected a 1-for-40 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Unaudited Condensed Consolidated Balance Sheets included herein:



	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	2,995	$	5,417
Restricted cash	254		332
Total cash, cash equivalents and restricted cash	$	3,249	$	5,749

Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $254 at September 30, 2020 and $332 at December 31, 2019 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.

Investments

The Company considers all investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term.

Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and certain changes in stockholders' equity that are excluded from net income (loss). The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive income (loss).

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to a level which, more likely than not, will be realized.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.

At September 30, 2020, 100% of the Company's total accounts and unbilled receivables are due from U.S. government grants.

Fair Value Measurements

The carrying amounts of the Company's financial instruments as of September 30, 2020 and December 31, 2019, which include cash equivalents, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements.

Segment Information

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Repairs and maintenance are charged to operating expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Right-of-Use Assets

The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, ("ASC 842") which requires lessees to recognize a lease liability and a corresponding lease asset for long-term lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The Company uses its incremental borrowing rate in calculating the present value of future lease payments when interest rates are not implicit in the lease. Leases with terms of 12 months or less at inception are expensed as costs are incurred and not capitalized under ASC 842.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.

Grant Revenue

The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered an ongoing major and central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets at September 30, 2020 and December 31, 2019. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.

Research and Development

All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, product trials, facility related expenses, depreciation, and stock-based compensation. Costs incurred in connection with government research grants are recorded as research and development expense.

General and Administrative Expenses

The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation expenses and office related expenses incurred to support the administrative operations of the Company.

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.

Recent Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. During the nine months ended September 30, 2020, the Company adopted the following new accounting guidance.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for the Company on January 1, 2020 and did not have a material impact on its disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows:

•

Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;


•	Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and


•	Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

This standard became effective on January 1, 2020. However, since the Company is not currently participating in any collaborative arrangements, the new standard does not impact its financial statements.

The following new pronouncement is not yet effective but may impact the Company's financial statements in the future.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on the Company’s condensed consolidated financial statements.

NATURE OF BUSINESS AND BASIS OF PRESENTATION	9 Months Ended
NATURE OF BUSINESS AND BASIS OF PRESENTATION	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION Yield10 Bioscience, Inc. is an agricultural bioscience company that uses its "Trait Factory" and the Camelina oilseed “Fast Field Testing” system to develop high value seed traits for the agriculture and food industries. Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada. The Company's goal is to efficiently develop superior gene traits for the major crops including corn, soybean, canola, and other crops to enable step-change increases in crop yield of at least 10-20 percent. Yield10's “Trait Factory” encompasses discovery of gene targets using its GRAIN (“Gene Ranking Artificial Intelligence Network”) big data mining platform, deployment of trait gene targets in the oilseed Camelina and generation of field performance data. The “Trait Factory” enables two complementary commercial opportunities with different paths to market. The first is trait licensing to the major seed companies for corn, soybean, canola and other crops. Data from the Company's trait field testing in Camelina has enabled Yield10 to establish research license agreements with leading seed companies including the Bayer Crop Science division of Bayer AG ("Bayer"), GDM, Forage Genetics International, LLC, a division of Land O'Lakes, Inc. ("Forage Genetics") and JR Simplot Company ("Simplot"). These companies are progressing the development of Yield10 traits in soybean, forage sorghum, and potato, respectively. The second commercial opportunity is to improve the performance and value of Camelina as a platform to develop a commercial crop product business producing nutritional oils and PHA biomaterials. Using this approach, Yield10 can leverage the resources of the major seed companies to efficiently develop superior gene traits for the major crops thereby creating opportunities for licensing revenue while focusing internal resources on trait gene discovery and the commercial development of Camelina products. The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statements of the financial position and results of operations for the interim periods ended September 30, 2020 and September 30, 2019. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2020. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. Except for a single year, the Company has recorded losses since its initial founding, including the three and nine months ended September 30, 2020. As of September 30, 2020, the Company held unrestricted cash, cash equivalents and short-term investments of $11,789. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. Based on its cash forecast, management expects that the Company's present capital resources will be sufficient to fund its planned operations for at least that period of time. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management may be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down its operations and pursue options for liquidating its remaining assets, including intellectual property. If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards and warrants.

The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units, convertible preferred stock and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and nine months ended September 30, 2020 and September 30, 2019, respectively, are shown below. Issued and outstanding warrants shown in the table below are described in greater detail in Note 12, contained herein.



	Three Months Ended September 30,		Nine Months Ended September 30,
	2020	2019	2020	2019
Options	317,706	61,310	183,346	51,386
Restricted Stock Awards	12,288	—	12,874	56
Series A Convertible Preferred Stock	—	—	17,013	—
Series B Convertible Preferred Stock	—	—	41,971	—
Warrants	2,843,699	175,995	2,843,699	175,995
Total	3,173,693	237,305	3,098,903	227,437

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. In addition, during November 2019, the Company issued Series A Warrants and Series B Warrants in two concurrent securities offerings. At the time of issuance, the Company determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and recognized at fair value due to the insufficiency of common shares available to permit their exercise. At December 31, 2019, the warrant liability met Level 3 classification criteria for classification within the fair value hierarchy. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.

The Company’s financial assets classified as Level 2 at September 30, 2020 and December 31, 2019 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade daily, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of September 30, 2020 and December 31, 2019.

The $14,977 fair value of the Series A and Series B Warrant liability at December 31, 2019 was determined using the Black-Scholes valuation model. The expected volatility and the risk free discount rate used in the Black-Scholes model were determined based on the Company's historical market price published on the Nasdaq Capital Market and from published U.S. Treasury yield curves, respectively, for a period matched to the contractual term of each warrant series.



At December 31, 2019	Series A Warrants	Series B Warrants
Fair market value of common stock (per share)	$6.86	$6.86
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

On January 15, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to effect a 1-for-40 reverse stock split. As a result of the reverse stock split, the Company's number of authorized but unissued shares of Common Stock increased significantly and the Series A Warrants and Series B Warrants issued under the offerings completed in November 2019 became eligible for exercise. Prior to reclassification as equity, on January 15, 2020, the Company adjusted the warrant liability to its then $15,934 fair value using the assumptions below, recording a loss on the adjustment to fair value of $957.



At January 15, 2020	Series A Warrants	Series B Warrants
Fair market value of common stock (per share)	$3.77	$3.77
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		September 30, 2020
Assets
Cash equivalents:
Money market funds	$	2,350	$	—	$	—	$	2,350
Short-term investments:
U.S. government and agency securities	—		8,794		—		8,794
Total assets	$	2,350	$	8,794	$	—	$	11,144



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government and agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977

There were no transfers of financial assets or liabilities between category levels for the three and nine months ended September 30, 2020 and the three and nine months ended September 30, 2019.

The Company owns 648,149 shares of Series A Redeemable Convertible Preferred Stock of Tepha, Inc. ("Tepha"), a privately held medical device company located in Lexington, Massachusetts, that is engaged in the development of medical device products that restore, maintain, or improve tissue function. The Company received the preferred shares from Tepha during 2002 in connection with a technology sublicense agreement that was later terminated during 2016. The preferred shares owned by the Company represent less than one percent of Tepha's current outstanding common shares on a fully diluted basis and were fully written off through an impairment charge during 2005 prior to Tepha initiating commercial product sales.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INVESTMENTS

9 Months Ended

Sep. 30, 2020

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS

Investments consist of the following at September 30, 2020 and December 31, 2019:



	Accumulated Cost at September 30, 2020		Unrealized				Market Value at September 30, 2020
	Accumulated Cost at September 30, 2020		Gain		(Loss)		Market Value at September 30, 2020
Short-term investments
Government securities	$	8,793	$	1	$	—	$	8,794
Total	$	8,793	$	1	$	—	$	8,794



	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
	Accumulated Cost at December 31, 2019		Gain		(Loss)		Market Value at December 31, 2019
Short-term investments
Government securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700

All short-term investments are classified as available for sale as of September 30, 2020 and December 31, 2019. The Company held no long-term investments at September 30, 2020, and December 31, 2019.

ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

ACCRUED EXPENSES

Accrued expenses consisted of the following at:



	September 30, 2020		December 31, 2019
Employee compensation and benefits	$	483	$	669
Leased facilities	101		51
Professional services	153		327
Other	193		279
Total accrued expenses	$	930	$	1,326

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

Expense Information for Employee and Non-Employee Stock Awards

The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $209 and $506 for the three and nine months ended September 30, 2020 and $131 and $406 for the three and nine months ended September 30, 2019, respectively. At September 30, 2020, there was approximately $2,141 of pre-tax stock-based compensation expense related to unvested awards not yet recognized.

The compensation expense related to unvested stock options is expected to be recognized over a remaining weighted average period of 3.38 years.

Stock Options

A summary of option activity for the nine months ended September 30, 2020 is as follows:



	Number of Shares		Weighted Average Exercise Price
Outstanding at December 31, 2019	62,065		$	178.95
Granted	266,192		$	5.93
Exercised	—		$	—
Forfeited	(721	)	$	48.40
Expired	(655	)	$	2,587.46
Outstanding at September 30, 2020	326,881		$	33.52

Vested and expected to vest at September 30, 2020	326,881		$	33.52
Options exercisable at September 30, 2020	66,176		$	127.65

Restricted Stock Units

The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. The Company then pays the minimum required income tax for the employees. During the nine months ended September 30, 2020 and September 30, 2019, the Company paid $17 and $4 for income tax withholdings associated with RSUs.

A summary of RSU activity for the nine months ended September 30, 2020 is as follows:



	Number of RSUs		Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2019	—
Awarded	17,000
Common stock issued upon vesting	(8,500	)
Forfeited	—
Outstanding at September 30, 2020	8,500		0.37

LEASES

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

LEASES

Lease Accounting

As a lessee, the Company follows the lease accounting guidance codified in ASC 842. Under ASC 842, a lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease. Any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. The Company's existing lease arrangements meet the standards for operating lease classification.

Under ASC 842, a lease liability is recorded on the commencement date of a lease and is calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company has adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.

Maturity Analysis of Lease Liabilities

At September 30, 2020, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2020 (October to December)	$	173
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	4,663
Discount	(937		)
Total lease liabilities	$	3,726
Short-term lease liability	$	443
Long-term lease liability	$	3,283

At September 30, 2020, the Woburn, Massachusetts facility is the only remaining lease included in the Company's right-of-use assets and corresponding lease liabilities.

Quantitative Disclosure of Lease Costs (unaudited)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Lease cost:
Operating lease cost	$	151		$	257		$	537		$	774
Short-term lease cost	167			139			473			393
Sublease income	(140		)	(126		)	(419		)	(385		)
Total lease cost, net	$	178		$	270		$	591		$	782

Other information as of:							September 30, 2020			December 31, 2019
Weighted-average remaining lease term (years)							6.2			6.7
Weighted-average discount rate							7.25%			7.24%

Real Estate Leases

During 2016, the Company entered into a lease agreement for its headquarters, pursuant to which the Company leased approximately 29,622 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. The lease agreement does not include any options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain taxes and operating costs associated with the premises throughout the term of the lease. During the buildout of the rented space, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that result in increased rental payments by the Company. Upon adopting ASC 842 these improvements were recorded as a reduction in the valuation of the right-of-use asset.

In November 2019, the Company entered into a modification agreement to the Woburn lease in which Yield10 returned 7,409 square feet of underutilized space to the landlord for the remaining term of the lease. In exchange for returning the space, the landlord agreed to fund modifications and upgrades to the office space retained by the Company. The modifications were completed in February 2020, and after that point the Company has no further financial obligations for the vacated space, including lease rental charges, utilities, maintenance and real estate tax charges. The Company's security deposit was also reduced from $307 to $229. During the first fiscal quarter of 2020, the Company wrote off $206 in leasehold improvements and office furniture, net of proceeds, associated with the returned space.

In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The CJ sublease is unaffected by the Company's recent lease modification with the landlord and it remains coterminous with the Company's master lease. CJ will pay pro rata rent and operating expenses equal to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $4,663 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

Through May 2020, the Company leased approximately 13,702 square feet of unused office and laboratory space in Lowell, Massachusetts. The lease terminated in accordance with the terms of the lease agreement and the facility has been returned to the landlord. No further expenses are anticipated under this lease.

The Company's wholly-owned subsidiary, Metabolix Oilseeds, Inc. ("MOI"), located in Saskatoon, Saskatchewan, Canada, leases approximately 6,900 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. MOI's leases for these facilities expire on various dates through May 2021.

CARES Act Loan	9 Months Ended
CARES Act Loan	Sep. 30, 2020
Debt Disclosure [Abstract]
CARES Act Loan	CARES ACT LOAN The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020 and subsequently amended by the Paycheck Protection Program Flexibility Act (the "Flexibility Act") on June 5, 2020, in order to provide relief from the economic impacts of COVID-19. During April 2020, the Company received $333 in loan proceeds from the Paycheck Protection Program (the “PPP”), established pursuant to the CARES Act and administered by the U.S. Small Business Administration. The unsecured loan (the “PPP Loan”) is evidenced by a promissory note of the Company dated April 19, 2020 in the principal amount of $333, issued to a third-party lender (the "lender"). The PPP Loan was amended as a result of the changes made by the Flexibility Act. Under the CARES Act and the PPP, the Company may apply for and be granted forgiveness for all or a part of the PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during the twenty-four-week period after the loan origination for certain purposes including payroll costs, rent payments on certain leases, and certain qualified utility payments. At least 60% of the loan amount must be used for eligible payroll costs; maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. In September 2020 the Company applied for forgiveness for the PPP Loan and is currently waiting for a determination to be made on its application. Under the terms of the PPP Loan, as amended, interest will accrue on the outstanding principal at the rate of 1.0% per annum. The term of the PPP Loan is two years from the date the loan proceeds were received, though it may be payable sooner in connection with an event of default under the terms of the PPP Loan. To the extent the loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning ten months from the date of the PPP Loan, until the maturity date. The PPP Loan may be prepaid in part or in full, at any time, without penalty. The PPP Loan provides for certain customary events of default, including, but not limited to, failing to make a payment when due under the loan, failure to take actions required by the loan, the Company defaulting under certain agreements in favor of any third party, making false statements, the Company’s insolvency, and the commencement of creditor or forfeiture proceedings against the Company. Upon the occurrence of an event of default, the lender has customary remedies and may, among other things, require immediate payment of all amounts owed under the PPP Loan, collect all amounts owed from the Company, and file suit and obtain judgment against the Company. During the Company's second quarter of 2020, it utilized the entire PPP Loan amount for qualifying expenses and has applied for loan forgiveness. Management of the Company considers it reasonably certain that it will meet the conditions for loan forgiveness, and as a result, the Company recorded the full amount of the loan, or $333, within other income (expense) in its condensed consolidated statement of operations during the nine months ended September 30, 2020.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Guarantees As of September 30, 2020, and December 31, 2019, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners and contractors. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of the indemnifications under these agreements is believed to be minimal. Accordingly, the Company has no liabilities recorded for these agreements as of September 30, 2020 and December 31, 2019.

GEOGRAPHIC INFORMATION

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

GEOGRAPHIC INFORMATION

The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below:



	U.S.		Canada		Eliminations			Total
Three Months Ended September 30, 2020:
Grant revenue from external customers	$	204	$	—	$	—		$	204
Inter-geographic revenues	—		625		(625		)	—
Revenues	$	204	$	625	$	(625	)	$	204

Three Months Ended September 30, 2019:
Grant revenue from external customers	$	224	$	—	$	—		$	224
Inter-geographic revenues	—		477		(477		)	—
Revenues	$	224	$	477	$	(477	)	$	224

Nine Months Ended September 30, 2020:
Net revenues from external customers	$	537	$	67	$	—		$	604
Inter-geographic revenues	—		1,403		(1,403		)	—
Net revenues	$	537	$	1,470	$	(1,403	)	$	604

Nine Months Ended September 30, 2019:
Net revenues from external customers	$	666	$	—	$	—		$	666
Inter-geographic revenues	—		1,313		(1,313		)	—
Net revenues	$	666	$	1,313	$	(1,313	)	$	666

Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. During the three and nine months ended September 30, 2020, revenue earned from the Company's Michigan State University sub-award represented 100.0% and 88.9%, respectively, of total government grant revenue for each period.

The geographic distribution of the Company’s long-lived assets is summarized as follows:



	U.S.		Canada		Eliminations		Total
September 30, 2020	$	894	$	41	$	—	$	935
December 31, 2019	$	1,186	$	57	$	—	$	1,243

CAPITAL STOCK AND WARRANTS

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

CAPITAL STOCK AND WARRANTS

Common Stock

Registered Public Offering

On August 26, 2020, the Company completed a public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. In addition, the underwriter exercised its over-allotment option to purchase 116,835 shares of common stock at the same price for total gross proceeds of $4,045 before issuance costs of $425. Of these issuance costs, $63 were outstanding as of September 30, 2020 and will be paid during the Company's fourth fiscal quarter. The shares of common stock were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-237539), as initially filed with the SEC on April 1, 2020 and declared effective on April 10, 2020.

Private Placement

Concurrent with the registered public offering described above, the Company completed a separate private placement offering of 396,450 shares of its common stock on August 26, 2020 to certain existing shareholders at the same $4.25 price offered to investors in the public offering. The gross proceeds from this private placement were $1,685.

Reverse Stock Split

On January 15, 2020, the Company completed a 1-for-40 reverse stock split ("Reverse Stock Split") of its common stock by filing a certificate of amendment (the "Charter Amendment") with the State of Delaware to amend its certificate of incorporation. The ratio for the Reverse Stock Split was determined by the Company's board of directors following approval by stockholders at the Company's special meeting held on January 9, 2020. The Reverse Stock Split had the effect of increasing the Company's common shares available for issuance by reducing issued and outstanding common shares by a divisible factor of 40 while its authorized common shares remained at the current 60 million shares. Proportional adjustments were made to the Company's outstanding stock options and to the number of shares issued and issuable under the Company's equity compensation plans.

November 2019 Concurrent Securities Offerings

On November 19, 2019, the Company closed on concurrent public and private securities offerings, receiving combined gross cash proceeds of $11,500, before issuance costs of $1,254.

The public portion of the offering included sales of Class A Units and Class B Units as follows:

•

405,750 Class A Units priced at a public offering price of $8.00 per unit, with each unit consisting of one share of common stock, par value $0.01 per share, Series A Warrants to purchase one share of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase one share of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The 405,750 Class A Units sold include the full exercise of the underwriter's over-allotment option of 93,750 Class A Units.

•

2,504 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of Series A Convertible Preferred Stock, par value $0.01 per share, convertible at any time at the holder's option into 125 shares of common stock, par value $0.01 per share, Series A Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The Series A Convertible Preferred Stock was convertible into shares of common stock at any time using a conversion ratio of $8.00 per share. As of April 30, 2020, all of the shares of the Series A Convertible Preferred Stock had converted to 313,000 shares of the Company's common stock.


•	Gross proceeds from the sale of Class A Units and Class B Units totaled $5,750.

In the concurrent private placement, certain existing shareholders purchased the following securities:

•

5,750 Units, priced at $1,000 per unit, each unit consisting of one share of the Company's Series B Convertible Preferred Stock, par value $0.01 per share, contingently convertible into 125 shares of common stock at an exercise price of $8.00, Series A Warrants to purchase 125 shares of common stock, par value $0.01 per share, at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering.


•	Gross proceeds from the private placement also totaled $5,750.

As of the November 19, 2019 closing date of the two offerings, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the Series B Convertible Preferred Stock sold in the private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued under both the public and the private offerings. The Series B Convertible Preferred Shares and the Series A Warrants and Series B Warrants were not convertible or exercisable until more shares of common stock became available for issuance through the Company's filing of the Charter Amendment for the Reverse Stock Split. Upon the filing of the Charter Amendment on January 15, 2020, all of the Series B Convertible Preferred Stock sold in the private placement automatically converted into 718,750 shares of common stock and the Series A Warrants and Series B Warrants issued in both offerings became eligible for exercise.

Until their conversion to common stock, the Company recorded the Series A Convertible Preferred Stock as permanent equity within the Company's balance sheet. The contingent redemption rights of the Series B Convertible Preferred stockholders were judged to be outside of the Company's control and resulted in their classification as temporary equity within the Company's balance sheet until their automatic conversion to common shares in January 2020.

The Series A and Series B Warrants are free standing financial instruments, legally detachable and separately exercisable from the common and preferred shares issued in the concurrent offerings. At the time of their issuance, the Company determined that all of the warrants should be classified as a warrant liability and recorded at an inception date fair value of $24,518 due to the insufficiency of common shares available to permit their exercise. As the proceeds from the offerings were less than the fair value of their respective warrants, the warrants were recorded at their full fair value and the difference between the fair value and the cash proceeds of $13,018 was recorded to other income (expense) in the Company's consolidated statement of operations during the year ended December 31, 2019. No residual offering proceeds remained to be allocated to the common and preferred shares sold in the offerings.

The Company re-measured the fair value of the warrants on December 31, 2019 and again on January 15, 2020 (the date of filing the Charter Amendment to increase available shares of common stock), resulting in, respectively, the recognition of a gain of $9,541 followed by a loss of $957, due to the change in fair value at each valuation date. By filing the Charter Amendment and enacting the 1-for-40 Reverse Stock Split, the Company's outstanding common shares were reduced by a divisible factor of 40 while authorized common shares remained at the current 60 million shares. As a result of this corporate action, sufficient shares of authorized, but unissued shares of common stock became available for Series A and Series B warrant holders to exercise their warrants resulting in their reclassification from warrant liability to equity in the Company's consolidated balance sheet.

At closing, the proceeds of the combined offerings were allocated solely to the liability classified warrants, and as a consequence, the offering costs of $1,254 were immediately expensed to other income (expense) in the consolidated statement of operations for the year ended December 31, 2019 in accordance with accounting guidance.

March 2019 Registered Direct Offering

On March 18, 2019, the Company completed a registered direct offering of its common stock. Proceeds from the transaction were $2,932 before issuance costs of $349. Investors participating in the transaction purchased a total of 60,541 shares of common stock at a price of $48.40 per share.

Preferred Stock

The Company's Certificate of Incorporation authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

Description of Series A Convertible Preferred Stock

The November 2019 public offering of the Company's securities included the issuance of 2,504 shares of Series A Convertible Preferred Stock. Each Series A Convertible Preferred Share was convertible into 125 shares of common stock at a conversion price of $8.00 per share. As of April 30, 2020, all 2,504 shares of the Series A Convertible Preferred Stock had converted to 313,000 shares of common stock.

Description of Series B Convertible Preferred Stock

The November 2019 private offering of the Company's securities included the issuance of 5,750 shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock was convertible into 125 shares of common stock at a conversion price of $8.00 per share. All of the Series B Convertible Preferred Stock converted automatically to 718,750 shares of common stock on January 15, 2020, upon the Company's filing of a Charter Amendment for the reverse stock split described above.

When converted, the shares of Series A and B Convertible Preferred Stock were restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Company's board of directors.

Warrants

The following table summarizes information regarding outstanding warrants to purchase common stock as of September 30, 2020:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price Per Share of Common Stock		Expiration Date
November 2019 Public Offering - Series A	580,727	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	649,477	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,843,699

February 2020 Warrant Exercises

In connection with the Company’s public securities offering that closed on November 19, 2019, the Company issued Series A Warrants and Series B Warrants to purchase shares of the Company’s common stock. The warrants were issued, and are held, in book-entry form through The Depository Trust & Clearing Corporation (“DTCC”). During early 2020, warrants equal to a total of 207,296 shares of the Company's common stock were exercised, generating cash proceeds of $1,658. In May 2020, Yield10 was informed by DTCC and its warrant agent that the exercise price of each warrant issued in the November 2019 public securities offering had been proportionately adjusted in accordance with the Company's 1-for-40 reverse stock split completed in January 2020, but that the number of shares issuable upon the exercise of each warrant had not been proportionately adjusted following the stock split within the records of DTCC. Based on DTCC's notification, the Company believed that up to 88,762 shares of common stock were incorrectly issued and up to $710 in proceeds were incorrectly collected for certain warrants exercised during February 2020. Following a thorough review with the warrant agent, DTCC and brokers for certain warrant holders who exercised these warrants, the Company determined that the number of shares of common stock issued and the amount of cash collected from the exercises were in fact correct, but that DTCC’s records did not accurately reflect the number of warrants remaining in the affected warrant holders’ accounts following their exercises. As of June 30, 2020, the issue was resolved by adjusting the DTCC accounts of the warrant holders. Accordingly, the Company was not required to return cash proceeds and the warrant holders were not required to return any of the common shares issued from the exercises. In its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, the Company recorded $710 within accrued expenses for the cash proceeds from the February 2020 warrant exercises that the Company previously expected to be returned to warrant holders. That accrual was relieved and reclassified to equity as of June 30, 2020.

Reserved Shares

The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:



	September 30, 2020	December 31, 2019
Stock Options	326,881	62,065
RSUs	8,500	—
Series A Convertible Preferred Stock - November 2019 Public Offering	—	99,500
Warrants	2,843,699	175,995
Total number of common shares reserved for future issuance	3,179,080	337,560

SUBSEQUENT EVENT (Notes)	9 Months Ended
SUBSEQUENT EVENT (Notes)	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On November 12, 2020, the Company entered into an exclusive collaborative research and development agreement with UK-based Rothamsted Research Limited (“Rothamsted”) for the development of engineered Camelina lines containing high levels of omega-3 fish oils. Yield10 will pay quarterly research funding and option fees totaling $250 over a two-year period in exchange for an exclusive right to internally evaluate Rothamsted technology. At any time during this two-year period, the Company can exercise an option to undertake negotiations with Rothamsted for an exclusive or non-exclusive worldwide commercial license that is expected to contain a one-time license fee and certain milestone and royalty payments based on achievement of regulatory and product sales objectives.

ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Investments

Use of Estimates

Foreign Currency Translation

Comprehensive Income (Loss)

Income Taxes

Concentration of Credit Risk

Fair Value Measurements

Segment Information

Property and Equipment



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Right-of-Use Assets

Impairment of Long-Lived Assets

Grant Revenue

Research and Development

General and Administrative Expenses

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-based Compensation

Stock-Based Compensation

Recent Accounting Standards

•


•	Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and


•	Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

The following new pronouncement is not yet effective but may impact the Company's financial statements in the future.

ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of Restricted Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Unaudited Condensed Consolidated Balance Sheets included herein:



	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	2,995	$	5,417
Restricted cash	254		332
Total cash, cash equivalents and restricted cash	$	3,249	$	5,749

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Unaudited Condensed Consolidated Balance Sheets included herein:



	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	2,995	$	5,417
Restricted cash	254		332
Total cash, cash equivalents and restricted cash	$	3,249	$	5,749

Estimated Useful Lives of Property and Equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares



	Three Months Ended September 30,		Nine Months Ended September 30,
	2020	2019	2020	2019
Options	317,706	61,310	183,346	51,386
Restricted Stock Awards	12,288	—	12,874	56
Series A Convertible Preferred Stock	—	—	17,013	—
Series B Convertible Preferred Stock	—	—	41,971	—
Warrants	2,843,699	175,995	2,843,699	175,995
Total	3,173,693	237,305	3,098,903	227,437

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair value measurement inputs



At January 15, 2020	Series A Warrants	Series B Warrants
Fair market value of common stock (per share)	$3.77	$3.77
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%



At December 31, 2019	Series A Warrants	Series B Warrants
Fair market value of common stock (per share)	$6.86	$6.86
Expected term (years)	2.3	7.3
Risk free rate	1.62%	1.83%
Volatility	127%	115%

Assets and liabilities measured at fair value on a recurring basis



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		September 30, 2020
Assets
Cash equivalents:
Money market funds	$	2,350	$	—	$	—	$	2,350
Short-term investments:
U.S. government and agency securities	—		8,794		—		8,794
Total assets	$	2,350	$	8,794	$	—	$	11,144



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government and agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977

INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2020

Investments, Debt and Equity Securities [Abstract]

Schedule of investment holdings

Investments consist of the following at September 30, 2020 and December 31, 2019:



	Accumulated Cost at September 30, 2020		Unrealized				Market Value at September 30, 2020
	Accumulated Cost at September 30, 2020		Gain		(Loss)		Market Value at September 30, 2020
Short-term investments
Government securities	$	8,793	$	1	$	—	$	8,794
Total	$	8,793	$	1	$	—	$	8,794



	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
	Accumulated Cost at December 31, 2019		Gain		(Loss)		Market Value at December 31, 2019
Short-term investments
Government securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700

ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consisted of the following at:



	September 30, 2020		December 31, 2019
Employee compensation and benefits	$	483	$	669
Leased facilities	101		51
Professional services	153		327
Other	193		279
Total accrued expenses	$	930	$	1,326

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Summary of option activity

A summary of option activity for the nine months ended September 30, 2020 is as follows:



	Number of Shares		Weighted Average Exercise Price
Outstanding at December 31, 2019	62,065		$	178.95
Granted	266,192		$	5.93
Exercised	—		$	—
Forfeited	(721	)	$	48.40
Expired	(655	)	$	2,587.46
Outstanding at September 30, 2020	326,881		$	33.52

Vested and expected to vest at September 30, 2020	326,881		$	33.52
Options exercisable at September 30, 2020	66,176		$	127.65

Schedule of restricted stock units activity

A summary of RSU activity for the nine months ended September 30, 2020 is as follows:



	Number of RSUs		Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2019	—
Awarded	17,000
Common stock issued upon vesting	(8,500	)
Forfeited	—
Outstanding at September 30, 2020	8,500		0.37

LEASES (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Maturity analysis of lease liabilities

At September 30, 2020, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2020 (October to December)	$	173
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	4,663
Discount	(937		)
Total lease liabilities	$	3,726
Short-term lease liability	$	443
Long-term lease liability	$	3,283

Quantitative disclosure of lease costs



	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Lease cost:
Operating lease cost	$	151		$	257		$	537		$	774
Short-term lease cost	167			139			473			393
Sublease income	(140		)	(126		)	(419		)	(385		)
Total lease cost, net	$	178		$	270		$	591		$	782

Other information as of:							September 30, 2020			December 31, 2019
Weighted-average remaining lease term (years)							6.2			6.7
Weighted-average discount rate							7.25%			7.24%

GEOGRAPHIC INFORMATION (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations

The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below:



	U.S.		Canada		Eliminations			Total
Three Months Ended September 30, 2020:
Grant revenue from external customers	$	204	$	—	$	—		$	204
Inter-geographic revenues	—		625		(625		)	—
Revenues	$	204	$	625	$	(625	)	$	204

Three Months Ended September 30, 2019:
Grant revenue from external customers	$	224	$	—	$	—		$	224
Inter-geographic revenues	—		477		(477		)	—
Revenues	$	224	$	477	$	(477	)	$	224

Nine Months Ended September 30, 2020:
Net revenues from external customers	$	537	$	67	$	—		$	604
Inter-geographic revenues	—		1,403		(1,403		)	—
Net revenues	$	537	$	1,470	$	(1,403	)	$	604

Nine Months Ended September 30, 2019:
Net revenues from external customers	$	666	$	—	$	—		$	666
Inter-geographic revenues	—		1,313		(1,313		)	—
Net revenues	$	666	$	1,313	$	(1,313	)	$	666

Schedule of the geographic distribution of long-lived assets

The geographic distribution of the Company’s long-lived assets is summarized as follows:



	U.S.		Canada		Eliminations		Total
September 30, 2020	$	894	$	41	$	—	$	935
December 31, 2019	$	1,186	$	57	$	—	$	1,243

CAPITAL STOCK AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Information with regard to outstanding warrants to purchase common stock

The following table summarizes information regarding outstanding warrants to purchase common stock as of September 30, 2020:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price Per Share of Common Stock		Expiration Date
November 2019 Public Offering - Series A	580,727	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	649,477	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,843,699

Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance

The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of RSUs and conversion of warrants:



	September 30, 2020	December 31, 2019
Stock Options	326,881	62,065
RSUs	8,500	—
Series A Convertible Preferred Stock - November 2019 Public Offering	—	99,500
Warrants	2,843,699	175,995
Total number of common shares reserved for future issuance	3,179,080	337,560

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) $ in Thousands	Sep. 30, 2020 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Unrestricted cash and cash equivalents and short-term investments	$ 11,789

- Additional Information (Details) $ in Thousands		9 Months Ended
- Additional Information (Details) $ in Thousands	Jan. 15, 2020	Sep. 30, 2020 USD ($) segment	Dec. 31, 2019 USD ($)
Concentration of credit risk
Reverse stock split, conversion ratio	0.025
Restricted cash \| $		$ 254	$ 332
Number of operating segments \| segment		1
Government Grants
Concentration of credit risk
Receivables/sales (as a percent)		100.00%
Equipment
Concentration of credit risk
Estimated useful life		3 years
Furniture and fixtures
Concentration of credit risk
Estimated useful life		5 years
Software
Concentration of credit risk
Estimated useful life		3 years

ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 2,995	$ 5,417
Restricted cash	254	332
Total cash, cash equivalents and restricted cash	$ 3,249	$ 5,749	$ 3,209	$ 3,355

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	3,173,693	237,305	3,098,903	227,437
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	317,706	61,310	183,346	51,386
Restricted Stock Awards
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	12,288	0	12,874	56
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	2,843,699	175,995	2,843,699	175,995
Series A Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	0	0	17,013	0
Series B Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	0	0	41,971	0

FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 15, 2020 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Nov. 19, 2019 USD ($)
Fair Value Disclosures [Abstract]
Warrant liability	$ 15,934	$ 0		$ 0		$ 14,977	$ 24,518
Gain (loss) for change in fair value of warrants	$ (957)	$ 0	$ 0	$ (957)	$ 0	$ 9,541
Reverse stock split, conversion ratio	0.025
Tepha
Equity Securities without Readily Determinable Fair Value [Line Items]
Investment owned (in shares) \| shares		648,149		648,149
Investment owned, percent (less than)		1.00%		1.00%

FAIR VALUE MEASUREMENTS - Fair Value Measurement Inputs (Details)	Jan. 15, 2020 $ / shares	Dec. 31, 2019 $ / shares	Nov. 19, 2019
Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term			2 years 6 months
Series A Warrants \| Fair market value of common stock (in dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	3.77	6.86
Series A Warrants \| Expected term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	2 years 3 months 19 days	2 years 3 months 19 days
Series A Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0162	0.0162
Series A Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.27	1.27
Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term			7 years 6 months
Series B Warrants \| Fair market value of common stock (in dollars per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	3.77	6.86
Series B Warrants \| Expected term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	7 years 3 months 19 days	7 years 3 months 19 days
Series B Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0183	0.0183
Series B Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.15	1.15

FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jan. 15, 2020	Dec. 31, 2019	Nov. 19, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 8,794		$ 5,700
Warrant liability	0	$ 15,934	14,977	$ 24,518
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	8,794		5,700
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	11,144		10,072
Warrant liability			14,977
Total liabilities			14,977
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	8,794		5,700
Fair Value, Measurements, Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,350		2,622
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			1,750
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	2,350		2,622
Warrant liability			0
Total liabilities			0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,350		2,622
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	8,794		7,450
Warrant liability			0
Total liabilities			0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	8,794		5,700
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			1,750
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0		0
Warrant liability			14,977
Total liabilities			14,977
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			$ 0

INVESTMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Accumulated Cost	$ 8,793	$ 5,700
Unrealized Gain	1	0
Unrealized (Loss)	0	0
Market Value	8,794	5,700
Long-term Investments	0	0
Government securities
Debt Securities, Available-for-sale [Line Items]
Accumulated Cost	8,793	5,700
Unrealized Gain	1	0
Unrealized (Loss)	0	0
Market Value	$ 8,794	$ 5,700

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 483	$ 669
Leased facilities	101	51
Professional services	153	327
Other	193	279
Total accrued expenses	$ 930	$ 1,326

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-based compensation
Stock-based compensation	$ 209	$ 131	$ 506	$ 406
Weighted Average Exercise Price
Taxes paid on employees' behalf related to vesting of stock awards			(17)	$ (4)
Employee stock option
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized	$ 2,141		$ 2,141
Weighted average remaining recognition period (years)			3 years 4 months 17 days
Options
Number of Shares
Outstanding at the beginning of the period (in shares)			62,065
Granted (in shares)			266,192
Exercised (in shares)			0
Forfeited (in shares)			(721)
Expired (in shares)			(655)
Outstanding at the end of the period (in shares)	326,881		326,881
Options vested and expected to vest at the end of the period (in shares)	326,881		326,881
Options exercisable at the end of the period (in shares)	66,176		66,176
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)			$ 178.95
Granted (in dollars per share)			5.93
Exercised (in dollars per share)			0.00
Forfeited (in dollars per share)			48.40
Expired (in dollars per share)			2,587.46
Outstanding at the end of the period (in dollars per share)	$ 33.52		33.52
Options vested and expected to vest at the end of the period (in dollars per share)	33.52		33.52
Options exercisable at the end of the period (in dollars per share)	$ 127.65		$ 127.65

STOCK-BASED COMPENSATION - RESTRICTED STOCK UNIT ACTIVITY TABLE (Details) - Restricted Stock Awards	9 Months Ended
	Sep. 30, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding (in shares)	0
Awarded (in shares)	17,000
Common stock issued upon vesting (in shares)	(8,500)
Forfeited (in shares)	0
Outstanding (in shares)	8,500
Weighted average remaining contractual life	4 months 13 days

LEASES - Narrative (Details) $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
LEASES - Narrative (Details) $ in Thousands	Nov. 30, 2019 ft²	Oct. 31, 2016 USD ($) ft²	Mar. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) ft²	Dec. 31, 2016 USD ($) ft²	Feb. 29, 2020 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Undiscounted future lease payments				$ 4,663
19 Presidential Way
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²					29,622
Operating leases, landlord reimbursement for lease improvements					$ 889
Operating leases, landlord reimbursement for lease improvements, additional payments					444
Area returned to landlord (in sqft) \| ft²	7,409
Letter of credit					$ 307	$ 229
Write off of leasehold improvements and office furniture, net of proceeds			$ 206
Subleased area (in sqft) \| ft²		9,874
650 Suffolk Street
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²				13,702
410 Downey Road and 110 Gymnasium Place
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²				6,900
CJ CheilJedang Corporation \| 19 Presidential Way
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Letter of credit		$ 103

LEASES - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020 (October to December)	$ 173
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	4,663
Discount	(937)
Total lease liabilities	3,726
Short-term lease liability	443	$ 602
Long-term lease liability	$ 3,283	$ 3,619

LEASES - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Lease cost:
Operating lease cost	$ 151	$ 257	$ 537	$ 774
Short-term lease cost	167	139	473	393
Sublease income	(140)	(126)	(419)	(385)
Total lease cost, net	$ 178	$ 270	$ 591	$ 782
Other information as of:
Weighted-average remaining lease term					6 years 8 months 15 days
Weighted-average discount rate	7.25%		7.25%		7.24%

CARES Act Loan CARES Act Loan (Details) - PPP Loan - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2020	Sep. 30, 2020	Apr. 19, 2020
Debt Instrument [Line Items]
Loan proceeds	$ 333
Principal amount			$ 333
Debt forgiveness income		$ 333

GEOGRAPHIC INFORMATION - Distribution of Revenues and Long-Lived Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Geographic Information
Revenue	$ 204	$ 224	$ 604	$ 666
U.S.
Geographic Information
Revenue	204	224	537	666
Canada
Geographic Information
Revenue	625	477	1,470	1,313
Operating segments
Geographic Information
Revenue	204	224	604	666
Operating segments \| U.S.
Geographic Information
Revenue	204	224	537	666
Operating segments \| Canada
Geographic Information
Revenue	0	0	67	0
Eliminations
Geographic Information
Revenue	(625)	(477)	(1,403)	(1,313)
Eliminations \| Canada
Geographic Information
Revenue	$ 625	$ 477	$ 1,403	$ 1,313

GEOGRAPHIC INFORMATION - Narrative (Details)	3 Months Ended	9 Months Ended
GEOGRAPHIC INFORMATION - Narrative (Details)	Sep. 30, 2020	Sep. 30, 2020
Grant \| Michigan State University \| Sales
Concentration risk
Concentration risk (as a percent)	100.00%	88.90%

GEOGRAPHIC INFORMATION - Schedule of Geographic Distribution (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Geographic Information
Long-lived assets	$ 935	$ 1,243
Reportable Geographical Components \| U.S.
Geographic Information
Long-lived assets	894	1,186
Reportable Geographical Components \| Canada
Geographic Information
Long-lived assets	41	57
Eliminations
Geographic Information
Long-lived assets	$ 0	$ 0

CAPITAL STOCK AND WARRANTS - Narrative (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 26, 2020 USD ($) $ / shares shares	Jan. 15, 2020 USD ($) shares	Nov. 19, 2019 USD ($) $ / shares shares	Mar. 18, 2019 USD ($) $ / shares shares	Feb. 29, 2020 USD ($) shares	Sep. 30, 2020 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Apr. 30, 2020 shares
Class of Stock [Line Items]
Reverse stock split, conversion ratio		0.025
Common stock, authorized (in shares)		60,000,000				60,000,000			60,000,000		60,000,000
Gross proceeds from transaction \| $			$ 11,500
Common stock, par value per share (in dollars per share) \| $ / shares			$ 0.01			$ 0.01			$ 0.01		$ 0.01
Preferred stock, par value per share (in dollars per share) \| $ / shares						0.01			0.01		0.01
Issuance of preferred stock in connection with private offering (in shares)			5,750
Preferred stock issued, price (in dollars per share) \| $ / shares			$ 1,000
Series B Convertible Preferred Stock, par value per share (in dollars per share) \| $ / shares			$ 0.01			$ 0.01			$ 0.01		$ 0.01
Number of securities called by warrants (in shares)			2,875,000			2,843,699			2,843,699
Warrant liability \| $		$ 15,934	$ 24,518			$ 0			$ 0		$ 14,977
Proceeds from issuance of warrants \| $			$ 13,018
Gain (loss) for change in fair value of warrants \| $		$ (957)				$ 0		$ 0	$ (957)	$ 0	$ 9,541
Preferred stock, authorized (in shares)											5,000,000
Proceeds from warrants exercised (Note 11) \| $							$ 1,658
Accrued warrant obligation - up to \| $					$ 710
Common Stock
Class of Stock [Line Items]
Cumulative issuances (in shares)												313,000
Common stock issued upon conversion (in shares)		718,750
Issuance of common stock for warrant exercise (in shares)							207,296		207,296
Common stock incorrectly issued in connection with warrant exercises - up to (in shares)					88,762
Series A Warrants
Class of Stock [Line Items]
Warrants, expected term			2 years 6 months
Exercise price of warrants (in dollars per share) \| $ / shares			$ 8
Series B Warrants
Class of Stock [Line Items]
Warrants, expected term			7 years 6 months
Exercise price of warrants (in dollars per share) \| $ / shares			$ 8
Class A Units
Class of Stock [Line Items]
Common stock included in each unit (in shares)			1
Class A Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right			1
Class B Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right			125
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value per share (in dollars per share) \| $ / shares			$ 0.01
Cumulative conversions (in shares)						2,504			2,504
Public and private offerings
Class of Stock [Line Items]
Issuance costs \| $			$ 1,254
Public offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $			$ 5,750
Issuance costs \| $	$ 425
Accrued Stock Offering Costs \| $						$ 63			$ 63
Common stock issued in offering (in shares)	835,000
Sale of Stock, Gross Consideration Received Per Transaction \| $	$ 4,045
Common stock price (in dollars per share) \| $ / shares	$ 4.25
Public offering \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)			405,750
Common stock price (in dollars per share) \| $ / shares			$ 8
Public offering \| Class B Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)			2,504
Common stock price (in dollars per share) \| $ / shares			$ 1,000
Over-allotment option
Class of Stock [Line Items]
Common stock issued in offering (in shares)	116,835
Over-allotment option \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)			93,750
Private placement / registered direct offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $				$ 2,932
Issuance costs \| $				$ 349
Common stock issued in offering (in shares)	396,450			60,541
Sale of Stock, Gross Consideration Received Per Transaction \| $	$ 1,685
Common stock price (in dollars per share) \| $ / shares	$ 4.25			$ 48.40

CAPITAL STOCK AND WARRANTS - Schedule Of Warrants Issuance (Details) - $ / shares	Sep. 30, 2020	Nov. 19, 2019
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	2,843,699	2,875,000
Warrants - expiration January 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	14,270
Exercise Price (in dollars per share)	$ 201.6
Warrants - expiration September 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	750
Exercise Price (in dollars per share)	$ 116
Public offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	580,727
Exercise Price (in dollars per share)	$ 8
Public offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	649,477
Exercise Price (in dollars per share)	$ 8
Public offering \| Series A Warrants - expiration December 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	160,975
Exercise Price (in dollars per share)	$ 90
Private offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in dollars per share)	$ 8
Private offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in dollars per share)	$ 8

CAPITAL STOCK AND WARRANTS - Schedule of Common Stock Reserved For Future Issuance (Details) - shares	Sep. 30, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	3,179,080	337,560
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	326,881	62,065
Restricted Stock Awards
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	8,500	0
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	0	99,500
Warrants
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	2,843,699	175,995

SUBSEQUENT EVENT (Details) - Subsequent Event - Rothamsted $ in Thousands	Nov. 12, 2020 USD ($)
Subsequent Event [Line Items]
Collaborative agreement, quarterly research funding and option fees payable	$ 250
Collaborative agreement, quarterly research funding and option fees payable, term	2 years